Medtronic PLC beat earnings as well as revenue estimates for the fiscal third quarter.
The healthcare device company’s earnings of $1.29 per cents per share for the quarter was higher five cents compared to than analysts’ estimates. Revenue of $2.12 billion edged past analysts’ expectations of $2.08 billion. Its minimally invasive therapies business, which makes surgical instruments and endoscopy products, was a major contributor to the sales performance.
Medtronic projects its full-year earnings to be in the range of $5.14 and $5.16 per share – that’s higher compared to its previous predicted range of $5.10 to $5.15 per share. Analysts are expecting earnings of $5.12 per share.
The company also revised its 2019 organic revenue growth forecast range upwards to 5.25% - 5.5 %, albeit with a caveat that a strong dollar would affect its full-year revenue by about $425 million to $475 million.
Omar Ishrak, Medtronic chairman and chief executive officer indicated that the company’s business diversification was an advantage in generating the strong sales figures. "Revenue outperformance in our Minimally Invasive Therapies and Restorative Therapies Groups, as well as broad strength across Emerging Markets, helped to offset certain market-specific headwinds we faced during the quarter, reflecting the full benefits of our diversification", Ishrak said.
MDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where MDT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on October 16, 2024. You may want to consider a long position or call options on MDT as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 16, 2024. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for MDT moved out of overbought territory on September 11, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MDT entered a downward trend on October 14, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.231) is normal, around the industry mean (22.725). P/E Ratio (27.625) is within average values for comparable stocks, (83.568). Projected Growth (PEG Ratio) (1.648) is also within normal values, averaging (5.667). Dividend Yield (0.032) settles around the average of (0.018) among similar stocks. P/S Ratio (3.588) is also within normal values, averaging (42.680).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of medical technology services
Industry MedicalSpecialties